Neuroscience diagnostics company presents new path to diagnosis and treatment of depression that 1 in 6 people suffer from during their lifetime

Ballast Group was identified by this neuroscience company’s patent lawyer in the middle of its research and development phase. The business goal was to generate awareness with a niche audience about its blood test that offers objective biological evidence for depression and prediction of antidepressant response. PAX focuses on a family of innovative screening and treatment products that are designed for rapid and reliable depression diagnosis and personalized therapy. Its approach offers a new path to diagnosis and treatment of depression that 1 in 6 people suffer from during their lifetime. 

The company led by Dr. Mark Rasenick, Chief Scientific Officer as husband-wife clinical, legal team had been invited to present at the annual JPMorgan Chase Health conference in San Francisco at the Sach’s and Associates 2nd annual neuroscience innovation forum. It did not yet have a solid, concise and compelling narrative as seen through the eyes of its many stakeholders. Deep diving into the science and technology, Ballast Group conducted a strategy session and stakeholder research to develop a story for seeking $11M beyond current academic and government grants to take the company through later-stage trials and into commercialization. Patients need and physicians seek first time accuracy in both a diagnosis and in the medications that align with a patient’s unique biology. We developed a company profile, MoodMark product and pipeline positioning, value proposition of demanding better solutions to address a public health emergency for depression – the leading cause of disability worldwide. 

Ballast Group’s inverted pyramid storytelling methodology designed a better way to explain what the Pax solution offered to prospective partners and what this means for the pharma, diagnostic and lab companies, physicians, patients, payers and the public. The presentation focused on team, science, two business segments, solutions to problems, three types of partners, IP and the intent for increased revenue stream, investors and research. We developed and designed a deck to translate Pax’s “why” and its value proposition to a financial audience. This presentation helped Pax secure invitations to present to two large, reputable drug companies.